Literature DB >> 25048289

Acute extrapyramidal syndrome induced by escitalopram: a case report.

Jagtar Singh Nimber1, Ashish Aggarwal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048289     DOI: 10.1007/s00213-014-3677-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  8 in total

Review 1.  Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses.

Authors:  H S Gill; C L DeVane; S C Risch
Journal:  J Clin Psychopharmacol       Date:  1997-10       Impact factor: 3.153

2.  Escitaloparm-induced paroxysmal dystonia.

Authors:  Pedro J Garcia Ruiz; Iria Cabo; Pablo Garcia Bermejo; Pablo Carnal
Journal:  Clin Neuropharmacol       Date:  2007 Mar-Apr       Impact factor: 1.592

Review 3.  Movement disorders associated with the serotonin selective reuptake inhibitors.

Authors:  R J Leo
Journal:  J Clin Psychiatry       Date:  1996-10       Impact factor: 4.384

4.  Escitalopram-induced Parkinsonism.

Authors:  Sertaç Ak; A Elif Anıl Yağcıoğlu
Journal:  Gen Hosp Psychiatry       Date:  2013-10-05       Impact factor: 3.238

5.  Dystonic rabbit syndrome from citalopram.

Authors:  Matthew M Parvin; Conrad M Swartz
Journal:  Clin Neuropharmacol       Date:  2005 Nov-Dec       Impact factor: 1.592

Review 6.  Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports.

Authors:  Subramoniam Madhusoodanan; Lada Alexeenko; Renata Sanders; Ronald Brenner
Journal:  Ann Clin Psychiatry       Date:  2010-08       Impact factor: 1.567

7.  Oculogyric dystonic reaction to escitalopram with features of anaphylaxis including response to epinephrine.

Authors:  Ojas P Patel; Michael R Simon
Journal:  Int Arch Allergy Immunol       Date:  2006-03-02       Impact factor: 2.749

Review 8.  Selective serotonin-reuptake inhibitor-induced movement disorders.

Authors:  P E Gerber; L D Lynd
Journal:  Ann Pharmacother       Date:  1998-06       Impact factor: 3.154

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.